timothy sykes logo
ImmunityBio Expands Reach with European Approval, IBRX Stock Gains Momentum Thumbnail
ADD US ONG Google News

ImmunityBio Expands Reach with European Approval, IBRX Stock Gains Momentum

ELLIS HOBBS•UPDATED MAR. 13, 2026, 11:32 AM ET
Reviewed by Matt Monaco Fact-checked by Bryce Tuohey

ImmunityBio Inc.’s stocks have been trading up by 8.25 percent, driven by investor optimism after promising clinical trial results.

Candlestick Chart

Live Update At 11:32:09 EDT: On Friday, March 13, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 8.25%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In the recent financial results, ImmunityBio reported 2025 revenues from Anktiva hitting approximately $113M, suggesting an impressive year-over-year growth of nearly 700%. Though, it’s also battling significant financial challenges. The company’s income statements portray a considerable deficit, marked by hefty R&D expenses and a convoluted array of liabilities. ImmunityBio’s balance sheet displays a total asset figure of around $501M, but with liabilities and shareholder equity casting a shadow over the positive revenue aspects.

The company’s expenses appear to outshine its income. We observe massive R&D costs pushing up the total expenses, while long-term debt and equity present numbers that require addressing. In contrast, the revenue per share has reached about $0.11, hinting at potential investor interest despite the financial hurdles. Significant unit growth, about 750%, indicates robust demand and uptake, which may encourage future investor confidence.

Looking closer at the stock’s performance, there’s been a noticeable climb, notably with a high of $8.46 recently, after a stable $7.82 closing the previous day. This movement is likely supported by recent international regulatory approvals boosting investor confidence. The company’s past few months’ stock charts suggest a consistent, albeit volatile, upward trend, coinciding with strategic announcements and market expansions.

Expanding Horizons: The Strategic Moves Pay Off

The latest announcements see ImmunityBio securing pivotal regulatory approvals in Europe for their flagship product, Anktiva, especially within the EU states. This opens doors to broader markets, reaching 33 countries. Such expansions potentially increase the revenue projections for the coming quarters, highlighting a bullish trend in stock prices.

In addition, they’ve inked a noteworthy partnership with Accord Healthcare, a move reinforcing their commercial and distribution efforts across Europe. These strategic steps address two vital aspects: regulatory compliance across new territories and logistical financial operations.

Furthermore, ImmunityBio’s focused push in Saudi Arabia, featuring alliances with Biopharma and Cigalah, aligns with Saudi regulatory directives to broaden cancer treatment access. Notably, this thrust into the MENA region reflects a compelling corporate strategy aimed at diversifying market presence beyond Western economies, appealing to a wide array of investors globally.

More Breaking News

Market Dynamics and Investor Implications

Navigating the complex realms of biotechnology and pharmaceutical investments demands a sharp eye on strategic expansions. ImmunityBio’s market revelations, highlighted by collaborations and extended drug approval portfolios, suggest a strategic bounce in their competitive edge.

ImmunityBio’s recent earnings updates further reveal a trajectory poised for greater market influence despite operating within a high-risk industry. The operational strategy points towards crafting long-term resilience by embracing R&D weighted strategies. This protective pivot could safeguard current traders and attract potential new ones, looking beyond immediate challenges.

The Crème de la Crème lies in consolidating these execution strategies while managing trader expectations amidst towering financial obligations. The narrative unfolding is one of evolving resilience amidst budding market alliances and strategic innovations paving potential profitability pathways.

In conclusion, while ImmunityBio’s financials highlight risks, the strategic partnerships and drug approvals speak of calculated growth ambitions. This blend of tactical maneuvers and financial oversight underlines a promising yet intricately woven story for potential, rewarding gains for traders vigilant enough to navigate the biopharma landscape. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” While the burdens of liabilities loom, diligent forecasts foresee a phased uplift powered by robust revenue forecasts and burgeoning commercial reach. As storylines align, the charts could paint a promising picture of an upward march in stock trajectory with calculated caution.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading IBRX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”